Helena Kandarova

Helena Kandarova

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2024 in Frontiers in Toxicology
Verified
Journal Article
Open access
HKHelena Kandarova
Helena Kandarova
PPPeter Pôbiš
Peter Pôbiš
Biocompatibility testing ensures the safety of medical devices by assessing their compatibility with biological systems and their potential to cause harm or adverse reactions. Thus, it is a critical part of the overall safety evaluation process for medical devices. Three primary types of biocompatibility tests—cytotoxicity, irritation, and sensitisation assessment—are standard for nearly all medical devices. However, additional biocompatibility tests, such as genotoxicity, systemic toxicity, hemocompatibility, and implantation studies, may also be necessary, depending on the device’s nature and intended use. The testing is partly conducted in vitro, but the industry still heavily relies on animal experiments. Compared to other industrial sectors, implementing alternatives in medical device biocompatibility testing has been notably slower. This delay can be attributed to the absence of specific validation processes tailored to medical devices and the resulting hesitation regarding the predictive capacity of these alternative methods despite their successful applications in other domains. This review focuses on the progress and obstacles to implementing new approach methodologies in the areas of cytotoxicity, irritation and sensitisation testing of medical devices. While challenges persist in adopting these innovative methods, the trend towards embracing alternatives remains robust. This trend is driven by technological advancements, ethical considerations, and growing industrial interest and support, all collectively contributing to advancing safer and more effective medical devices.


1 January 2020 in ALTEX
Verified
Journal Article
Open access
PDF file
ALAlžbeta Líšková
Alžbeta Líšková
SLSilvia Letašiová
Silvia Letašiová
SJSoňa Jantová
Soňa Jantová
VBVlasta Brezová
Vlasta Brezová
HKHelena Kandarova
Helena Kandarova
Despite a continuous increase of number of commercial products containing nanoparticles, only few materials are currently used in such large amounts, forms and sizes as Titanium dioxide - TiO2. Besides its use in cosmetics, food industry and biomedicine, TiO2 nanoparticles (NPs) are also used as highly efficient photocatalysts due to their unique ability to convert complex organic materials to carbon dioxide, water and simple mineral acids via complex radical and electron transfer reactions. The main objective of the current project was to assess the potential dermal effect (phototoxicity and skin toxicity) of TiO2 nanosheets (TIG-800) synthesized from the lyophilized aqueous colloids of peroxotitanic acid by high-temperature treatment. The effect was examined on reconstructed human skin model EpiDerm in the test pre-validated by ECVAM and adopted into the ICH S10 guidelines for the pre-clinical photo-safety assessment of the drugs. Along with the TiO2 nanosheets, two additional commercial samples of nanocrystalline TiO2, namely Aeroxide-P25 and Eusolex T-2000 and 6 benchmark materials from pre-validation studies were tested. None of the TiO2 NPs tested in the study caused phototoxicity or cytotoxicity up to the highest concentration tested. Results obtained for the benchmark chemicals were the same or better in comparison to published data. This has been achieved by improved dosing, conditions of irradiation and choice of suitable solvents. In order to completely eliminate doubts associated with possible, yet undiscovered dermal effects, skin penetration studies of this new form of TiO2 should be undertaken to determine, whether the penetrated amounts may pose any toxicology concern.

1 November 2020 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
LSL. Svobodova
L. Svobodova
MDMarketa DVORAKOVA
Marketa DVORAKOVA
MRMarian Rucki
Marian Rucki
KKK. Kejlova
K. Kejlova
HKHelena Kandarova
Helena Kandarova
THT. Heinonen
T. Heinonen

19 October 2024 in Toxicology in Vitro
Verified
Journal Article
Closed access
PPPeter Pôbiš
Peter Pôbiš
TMTatiana Milasová
Tatiana Milasová
HKHelena Kandarova
Helena Kandarova

1 August 2020 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
KKKristina Kejlová
Kristina Kejlová
HBHana Bendová
Hana Bendová
JCJan Chrz
Jan Chrz
MDMarkéta Dvořáková
Markéta Dvořáková
LSLada Svobodova
Lada Svobodova
HKHana Kolářová
Hana Kolářová